BMJ Group: For Women With Primary Progressive Multiple Sclerosis, Could Roche's Best Selling Drug Be Doing More Harm Than Good?
April 18, 2026
April 18, 2026
LONDON, England, April 18 (TNSjou) -- BMJ Group issued the following news release about The BMJ:
* * *
For women with primary progressive multiple sclerosis, could Roche's best selling drug be doing more harm than good?
Investigation explores how an $80,000 a year drug was approved for primary progressive form of MS despite concerns over its safety and effectiveness
*
The US Food and Drug Administration (FDA) is reviewing a p . . .
* * *
For women with primary progressive multiple sclerosis, could Roche's best selling drug be doing more harm than good?
Investigation explores how an $80,000 a year drug was approved for primary progressive form of MS despite concerns over its safety and effectiveness
*
The US Food and Drug Administration (FDA) is reviewing a p . . .